Global Human Recombinant Insulin Market – Analysis and Forecast (2018-2024)

1. Human Recombinant Insulin Market

2. About VynZ Research… • VynZ Research is a global market research firm offering research, analytics, and consulting services on business strategies. We have a recognized trajectory record and our research database is used by many renowned companies and institutions in the world to strategize and revolutionize business opportunities. The company focuses on providing valuable insights on various technology verticals such as Chemicals, Automotive, Transportation, Energy, Consumer Durables, Healthcare, ICT and other emerging technologies. • VynZ Research has one of the most qualified & experienced analysts, who are constantly tracking the markets and the technologies. The research team has years of proven experience and wide knowledge & understanding of the technology, application, business models, and regulators of the segments and the value chain involved. • A trusted & proven methodology that involves highest quality of primary research, secondary analysis collated & verified through various sources including cross checking with different industry experts. • Serving wide range of customers most of them from Fortune 2000 companies • With a dedicated 24x7 customer helpline our customers can reach for specifying their needs • Developing long term relationship with the clients and satisfying them is one of the crucial notches of the company. VynZ Research aims at gaining and retaining its clients in order to make long term customer relationship.

3. Human Recombinant Insulin Market Human recombinant insulin is the synthetic insulin, resulted utilizing recombinant DNA technology. The global human recombinant insulin market is growing at significant rate, due to mounting occurrence diabetes and mounting need for human insulin analogs. Different product type contributed to the human recombinant insulin market size. The market has witnessed high demand for long acting human insulin in the coming years due to advanced competence and capability to pose constant insulin delivery during the day.

4. Human Recombinant Insulin Market Mounting number of diabetic patients, promising medical reimbursement setup in developed countries, escalating risk factors leading to diabetes, intensifying market availability of generic human insulin products and mounting need for human insulin analogs are the primary growth drivers for human recombinant insulin market. For instance, according to World Health Organization (WHO), globally the number of people with diabetes has risen from 108 million in 1980 to 422 million in 2014. In addition, according to IDF in 2017, globally approximately 425 million adults were suffering from diabetes and are expected to reach 629 million in 2045. Expected patent expiry of major human analog drugs, expanding geriatric population, mounting R&D for drug discovery & development and technological advancement in human insulin delivery devices are also facilitating the growth for the human recombinant insulin market.

5. Human Recombinant Insulin Market Asia-Pacific is observed to witness fastest growth in the market, due to mounting number of diabetic patients. In addition, mounting healthcare expenditure, developing regulatory skeleton for promoting approvals & medical repayments, reinforcing distribution networks of product manufacturers and expanding awareness about diabetes are also creating a positive impact on the human recombinant insulin market growth in the region. Key players in the human recombinant insulin market are catering the demand of these devices by investing on technologically advanced products in their product portfolio across the globe. In August 2018, Novo Nordisk A/S acquired Ziylo, to accelerate development of glucose responsive insulin for therapeutic and diagnostic applications. Novo Nordisk A/S, Biocon Limited, Sanofi S.A., Wanbang Biopharmaceuticals Co., Ltd., Bioton S.A., Eli Lilly and Company, Zhuhai United Laboratories Co., Ltd., Julphar Gulf Pharmaceutical Industries, Dongbao Enterprise Group Co., Ltd, and Gan & Lee Pharmaceuticals, Ltd. are the key players offering human recombinant insulin products.

6. For Sample Report :- https://www.vynzresearch.com/healthcare/human-recombinant-insulin-market/request-sample www.vynzresearch.com